Actively Recruiting
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Led by Stanford University · Updated on 2026-02-09
46
Participants Needed
1
Research Sites
415 weeks
Total Duration
On this page
Sponsors
S
Stanford University
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.
CONDITIONS
Official Title
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with suspected or confirmed diagnosis of glioblastoma (cohorts 1, 2, and 3) or vestibular schwannoma (cohort 4)
- Planned surgical removal of the tumor as part of standard care, including those post-chemotherapy, post-radiation, or after diagnostic biopsy
- Age 18 years or older
- Willing and able to provide informed consent and comply with all study procedures and visits
You will not qualify if you...
- Received an investigational drug within 30 days before the first dose of Panitumumab-IRDye800
- History of heart attack, stroke, uncontrolled heart failure, significant liver disease, or unstable angina within 6 months prior to enrollment
- History of infusion reactions to monoclonal antibody therapies
- Pregnant or breastfeeding
- Evidence of QTc prolongation on pretreatment ECG (greater than 440 ms in males or 460 ms in females)
- Platelet count less than 75,000/mm3
- TSH of 13 micro International Units/mL or higher
- Low magnesium, potassium, or calcium levels below normal range
- Serum creatinine more than 1.5 times the upper limit of normal
- Use of Class IA or Class III antiarrhythmic medications
- History or evidence of interstitial pneumonitis or pulmonary fibrosis
- Deemed inappropriate for optimal tumor resection by the investigator due to tumor location or other factors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford University School of Medicine
Palo Alto, California, United States, 94304
Actively Recruiting
Research Team
S
Sandra Torres
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here